

# Index Ventures Life Sciences

---

## ASSET CENTRIC INVESTMENT STRATEGY



# Index Ventures Life Sciences

---

- One asset per company
- Focus on 'killer experiment'
- Early-stage bias, POC within €12-15m
- 3 years +/- 1 year cycle
- Heavily involved in building & transacting




# General Descriptors of the Investing Strategy

---

- Only 1 (max 2) molecules per company  
80% of capital goes to lead asset
- More than 80% of costs are kept variable  
SWAT teams instead of FTEs  
and no infrastructure built before POC
- Key member of management team associated with Index  
Serial backing, one molecule at a time, time  
spent on wrong molecule bears high opportunity cost,  
but no impact on job security
- Index retains strong influence  
both at the operational as well as at shareholder level




# Summary of Activities (2012-2014)



# Index Life 6 Pipeline

18 programs: 4 Clinical, 5 Preclinical, 9 Research



# Molecules by Type

## Biologics

**Stealthyx**  
oncology

**Serpin H**  
Serin protease inhibitor

**AEP11**  
APOE3-derived peptide

**TCF**  
Antigen specific T Cells

**Encare**  
Anti-EDA mAb

**P75**  
Soluble NGF receptor

**GS-010**  
AAV-ND4

**Ichorchumab**  
Thrombin binding mAb

**GS-020**  
AAV-Halorhodopsin

## Small Molecules

**Ega 001**  
TR-Morphine

**Ega-002**  
TR-Oxycodon

**Ega-003**  
TR-Hydrocodon

**Janpix**  
Stat3 inhibitor

**Purple**  
PCSK9 inhibitor

**FXL 125**  
Sstr2-binder  
(somatotaxin)

**SKW48**  
APOE3 antagonist

**Methusalah**  
Proteome "protectors"

**Inhibitaxin**  
Autotaxin inhibitor



# Index Ventures Life Sciences

---

- 'Asset-centric' investing strategy
- Focus on 'killer experiment'
- Early-stage bias, POC within €12-15m
- Heavily involved in building & transacting

